Login to Your Account

FDA Fast Tracks AiCuris' Cytomegalovirus Drug AIC246

By Cormac Sheridan

Friday, September 2, 2011
AiCuris GmbH & Co. KG gained FDA fast-track designation – and valuable mindshare – for its lead drug AIC246 (letermovir), a viral terminase inhibitor that combats human cytomegalovirus (CMV) infection. It is currently undergoing a Phase IIb trial in bone marrow transplant recipients, who are receiving the drug prophylactically, in order to prevent the dormant virus from re-emerging and causing active infection.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription